학술논문

Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin (R)) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)
Document Type
Journal
Source
CANCER RESEARCH; JUN 15 2022, 82 12, 2p. Supplement: S
Subject
Language
English
ISSN
15387445